Edwards Lifesciences Gets European OK on Therapy
- Share via
Edwards Lifesciences Corp. said Thursday that it has won approval from European regulators to sell its next-generation treatment for abdominal aortic aneurysms, which are potentially life-threatening.
The product, called Lifepath AAA Endovascular Graft System, is a less-invasive treatment for the condition, which involves a weakening and ballooning of the wall of the aorta, the body’s main circulatory channel.
Irvine-based Edwards said it will begin commercial roll-out of the new product immediately.
The company’s stock edged up 27 cents to $22.32 Thursday on the New York Stock Exchange.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
